scholarly journals Advances in Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 72 (1) ◽  
pp. 119-134
Author(s):  
Michael C. Ferrera ◽  
Wassim W. Labaki ◽  
MeiLan K. Han
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Respiratory Disorder ◽  
Significant Morbidity ◽  
Disease Pathogenesis ◽  
Obstructive Pulmonary Disease ◽  
The Past ◽  
Disease Modifying Therapy ◽  
Disease Modifying

Chronic obstructive pulmonary disease (COPD) is a common respiratory disorder with significant morbidity and mortality. Despite its prevalence, COPD is underdiagnosed, and many patients do not receive a diagnosis until the disease is clinically advanced. Recent basic science and clinical research have focused on the early physiologic and pathobiologic changes in COPD with the hopes of improving diagnosis, providing targets for disease-modifying therapy, and identifying patients most likely to benefit from early intervention. Available treatments for COPD have grown substantially in the past 20 years with the introduction of new oral and inhaled medications as well as novel surgical and bronchoscopic procedures. This article summarizes some of the recent advances in our understanding of disease pathogenesis and treatment paradigms.

scholarly journals Aberrant Post-Transcriptional Regulation of Protein Expression in the Development of Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 22 (21) ◽  
pp. 11963
Author(s):  
Noof Aloufi ◽  
Aeshah Alluli ◽  
David H. Eidelman ◽  
Carolyn J. Baglole
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Transcriptional Regulation ◽  
Pulmonary Disease ◽  
Rna Binding ◽  
Rna Binding Proteins ◽  
Chronic Obstructive ◽  
Respiratory Disorder ◽  
Obstructive Pulmonary Disease ◽  
Cellular Processes ◽  
Post Transcriptional Regulation

Chronic obstructive pulmonary disease (COPD) is an incurable and prevalent respiratory disorder that is characterized by chronic inflammation and emphysema. COPD is primarily caused by cigarette smoke (CS). CS alters numerous cellular processes, including the post-transcriptional regulation of mRNAs. The identification of RNA-binding proteins (RBPs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs) as main factors engaged in the regulation of RNA biology opens the door to understanding their role in coordinating physiological cellular processes. Dysregulation of post-transcriptional regulation by foreign particles in CS may lead to the development of diseases such as COPD. Here we review current knowledge about post-transcriptional events that may be involved in the pathogenesis of COPD.

Exploring the link between scavenger receptor B1 expression and chronic obstructive pulmonary disease pathogenesis

2015 ◽  
Vol 1340 (1) ◽  
pp. 47-54 ◽  
Author(s):  
Giuseppe Valacchi ◽  
Emanuela Maioli ◽  
Claudia Sticozzi ◽  
Franco Cervellati ◽  
Alessandra Pecorelli ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Scavenger Receptor ◽  
Chronic Obstructive ◽  
Disease Pathogenesis ◽  
Obstructive Pulmonary Disease

Extracorporeal Support for Chronic Obstructive Pulmonary Disease: A Bright Future

2016 ◽  
Vol 32 (7) ◽  
pp. 411-420 ◽  
Author(s):  
John M. Trahanas ◽  
William R. Lynch ◽  
Robert H. Bartlett
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Invasive Mechanical Ventilation ◽  
Chronic Obstructive ◽  
Controlled Trials ◽  
Obstructive Pulmonary Disease ◽  
The Past ◽  
Extracorporeal Support ◽  
Removal System

In the past the only option for the treatment of respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease (aeCOPD) was invasive mechanical ventilation. In recent decades, the potential for extracorporeal carbon dioxide (CO2) removal has been realized. We review the various types of extracorporeal CO2 removal, outline the optimal use of these therapies for aeCOPD, and make suggestions for future controlled trials. We also describe the advantages and requirements for an ideal long-term ambulatory CO2 removal system for palliation of COPD.

PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy

2019 ◽  
Vol 26 (16) ◽  
pp. 2791-2800 ◽  
Author(s):  
Flora Pirozzi ◽  
Kai Ren ◽  
Alessandra Murabito ◽  
Alessandra Ghigo
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Drug Targets ◽  
Airflow Obstruction ◽  
Chronic Obstructive ◽  
Respiratory Disorder ◽  
Pi3k Signaling ◽  
Obstructive Pulmonary Disease ◽  
Promising Alternative ◽  
Molecular Therapeutic

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disorder characterized by irreversible chronic inflammation and airflow obstruction. It affects more than 64 million patients worldwide and it is predicted to become the third cause of death in the industrialized world by 2030. Currently available therapies are not able to block disease progression and to reduce mortality, underlying the need for a better understanding of COPD pathophysiological mechanisms to identify new molecular therapeutic targets. Recent studies demonstrated that phosphoinositide 3-kinase (PI3K) signaling is prominently activated in COPD and correlates with an increased susceptibility of patients to lung infections. PI3Ks have thus emerged as promising alternative drug targets for COPD and a wide array of pan-isoform and isoform-selective inhibitors have been tested in preclinical models and are currently being evaluated in clinical studies. Here, we summarize the recent knowledge on the involvement of PI3K enzymes in the pathophysiology of COPD, and we discuss the most recent results arising from the preclinical as well as the clinical testing of PI3K inhibitors as novel therapeutics for COPD.

Management of patients with chronic obstructive pulmonary disease in COVID-19 pandemic

2020 ◽  
Vol 1 (19) ◽  
pp. 77-80
Author(s):  
S. I. Krayushkin ◽  
I. V. Ivakhnenko ◽  
E. A. Sushchuk ◽  
A. V. Zaporoshchenko
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Maintenance Therapy ◽  
Pulmonary Disease ◽  
Stable Condition ◽  
Adverse Outcomes ◽  
Chronic Obstructive ◽  
Significant Morbidity ◽  
Obstructive Pulmonary Disease ◽  
Increased Risk ◽  
Coronavirus Infection

The pandemic of COVID-19, a disease caused by a novel coronavirus SARS-CoV-2, is associated with significant morbidity and mortality. Recent data showed that patients with chronic obstructive pulmonary disease (COPD) have an increased risk for severity and complicated COVID-19 infection. In coronavirus pandemic, patients with COPD should continue standard maintenance therapy, including bronchodilators and their combination with inhaled glucocorticosteroids, in order to maintain a stable condition and prevent the development of exacerbations that can be provoked by COVID-19. It is important for this group of patients to carefully monitor the condition and follow measures aimed at preventing infection with coronavirus infection due to the increased risk of adverse outcomes.

Sign in / Sign up

Export Citation Format

Share Document